MedTrace Logo

A Study to Evaluate the Effects of RAD1901 in the Treatment of Vasomotor Symptoms in Postmenopausal Women

NCT00875420 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2018-09-26

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether RAD1901 is effective in decreasing hot flashes in postmenopausal women.

Conditions

Interventions

DRUG

RAD1901

10 mg Oral once a day for 28 days.

DRUG

RAD1901

25 mg Oral once a day for 28 days

DRUG

RAD1901

50 mg Oral once a day for 28 days.

DRUG

RAD1901

100 mg Oral once a day for 28 days

DRUG

Placebo

Placebo Oral once a day for 28 days

Sponsors & Collaborators

  • Radius Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director · Radius Health, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2010-01-31
Completion
2010-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00875420 on ClinicalTrials.gov